Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Roberts Website

David D. Roberts, Ph.D.

Portait Photo of David Roberts
Laboratory of Pathology
Head, Biochemical Pathology Section
Senior Investigator
Center for Cancer Research
National Cancer Institute
Building 10, Room 2A27
Bethesda, MD 20892-1500
Phone:  
301-594-5256
Fax:  
301-402-0043
E-Mail:  
droberts@helix.nih.gov

Biography

Dr. Roberts received his B.S. in Chemistry from the Massachusetts Institute of Technology and his Ph.D. in Biological Chemistry from The University of Michigan. After postdoctoral training at Michigan and in the Laboratory of Biochemical Pharmacology of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), he became a research chemist in the NIDDK and later joined the NCI as chief of the Biochemical Pathology Section. He serves on peer review panels and on the editorial boards of the Journal of Biological Chemistry, PLoS One, Scientific Reports, and Cellular and Molecular Life Sciences. His research interests include tumor cell-matrix interactions, angiogenesis, redox biology, the biochemistry of cell surface carbohydrates, and host-pathogen interactions.

Research

Regulation of Cellular Function and Gene Expression by Extracellular Matrix Components in Tumor Cells and Opportunistic Pathogens

The major focus of the Roberts lab is to define functions of the extracellular matrix protein thrombospondin-1, its receptors, and downstream signal transduction pathways in cancer. Our current major objectives are 1) to identify mechanisms by which thrombospondin-1 signaling through its receptor CD47 regulates angiogenesis and tumor perfusion, 2) to define CD47 signaling pathways that differentially regulate self-renewal and autophagy in normal versus tumor cells, 3) to understand the mechanisms by which thrombospondin-1 regulates anti-tumor adaptive immunity, and 4) identifying genes required for disseminated infections by the pathogenic yeast Candida albicans.. All of these projects include translational aims employing novel therapeutic agents that we have developed.

Our previous work established that several integrin and non-integrin receptors mediate the complex actions of thrombospondin-1 on vascular cells. Of these, CD47 is the necessary receptor for inhibiting angiogenesis and tumor perfusion. Thrombospondin-1 signaling through CD47 redundantly inhibits the nitric oxide (NO)/cGMP cascade in vascular endothelial and smooth muscle cells. Through this pathway thrombospondin-1/CD47 signaling simultaneously inhibits tumor angiogenesis and perfusion. In addition, we discovered that CD47 interacts directly with VEGF receptor-2 and inhibits its signaling. The NO/cGMP cascade is only one of several signaling pathways that mediate the pro-angiogenic activities of VEGF, so we now recognize that the anti-angiogenic activities of thrombospondin-1/CD47 signaling extend beyond the NO/cGMP cascade. We are developing peptide and small molecule mimetics of thrombospondin-1 that can be used to therapeutically inhibit tumor angiogenesis and perfusion.

Initially focusing on the NO/cGMP pathway, we predicted that antagonists of thrombospondin-1/CD47 signaling would improve tissue survival of ischemic injuries by enhancing NO-dependent tissue perfusion. We developed novel antagonists and confirmed this hypothesis in several animal injury models, but remarkably, the prosurvival activity of CD47 blockade extended to injuries that are independent of NO signaling including those caused by ionizing radiation. Our mechanistic studies established that CD47 blockade directly enhances survival of nontransformed cells under stress by stimulating a protective autophagy response and by inducing expression of c-Myc and several additional transcription factors that promote stem cell self-renewal. Applying these insights, we showed that systemic suppression of CD47 expression in tumor-bearing mice protected radiosensitive tissues from damage caused by irradiation, but the tumors became more sensitive to radiation.

In addition to being a thrombospondin-1 receptor, CD47 is a counter-receptor for the inhibitory self-recognition receptor SIRPα on phagocytes. As such, CD47/SIRPα antagonists have recently attracted publicity as potential therapeutics for enhancing anti-tumor innate immunity. Although we can confirm this activity, we find that thrombospondin-1, not SIRPα, is required for the synergism between CD47 blockade and therapeutic irradiation. We are studying the molecular mechanisms but also focusing on the practical application of this discovery to enhance immunotherapy of cancer.

Host colonization and vascular dissemination of Candida albicans. Because clinical isolates of Candida sp. are increasingly resistant to the available antifungal agents, new approaches are needed to prevent and treat these infections in cancer patients. We found that hemoglobin specifically induces expression of a C. albicans receptor for the host matrix protein fibronectin. This response is mediated by a hemoglobin receptor and is conserved among pathogenic species in the Candida genus. We identified a hemoglobin-induced cell wall protein that binds to fibronectin and cloned several novel genes that are rapidly induced in cells exposed to hemoglobin in vitro or by incubation in the vascular compartment of rabbits. One of these genes, HBR1, is essential for vegetative growth and is haploinsufficient for regulation of mating type locus genes, white-opaque switching, and some stress responses. A second hemoglobin-induced gene was identified as a heme oxygenase, which is essential for growth on iron-limiting medium and metabolizes exogenous heme to α-biliverdin. These changes in gene expression define a new differentiation pathway by which C. albicans adapts to the vascular compartment of its host. Understanding the signal transduction pathways that regulate this differentiation pathway could lead to new therapeutic targets to manage disseminated candidemia.

Recent Publications:

Soto-Pantoja, et al, CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 8:1628-1642, 2012.

Soto-Pantoja, et al, Inhibitory signaling through signal regulatory protein-alpha is not sufficient to explain the anti-tumor activities of CD47 antibodies. Proc. Natl. Acad. Sci. USA 109:E2842, 2012.

Martin-Manso, et al, Endogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasis. PLoS One 7:e48775, 2012.

Soto-Pantoja, et al, Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47. Expert Opin. Ther. Targets 17:89-103, 2013.

Soto-Pantoja, et al, Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci. Rep. 3:1038, 2013.

Miller, et al, Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol. 32:316, 2013.

Kaur, et al, CD47 inhibits self-renewal and reprogramming by limiting c-Myc and other stem cell transcription factors. Sci. Rep. 3:1673, 2013.

Soto-Pantoja, et al, Thrombospondin-1 and CD47 signaling regulate healing of thermal injury in mice. Matrix Biol. In press

Kaur, et al, CD47-dependent immunomodulatory and angiogenic activities of extracellular vesicles produced by T cells. Matrix Biol. In press

This page was last updated on 6/25/2014.